Metabolic Alterations and Related Biological Functions of Post-Stroke Depression in Ischemic Stroke Patients
Lulu Wen,Chuming Yan,Wancheng Zheng,Yi Li,Yuhui Wang,Miao Qu
DOI: https://doi.org/10.2147/NDT.S415141
IF: 2.989
2023-07-07
Neuropsychiatric Disease and Treatment
Abstract:Lulu Wen, 1 Chuming Yan, 1 Wancheng Zheng, 1 Yi Li, 2 Yuhui Wang, 2 Miao Qu 1 1 Neurology Department, Xuan Wu Hospital Capital Medical University, Beijing, People's Republic of China; 2 Neurology Department, Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China Correspondence: Miao Qu, Neurology Department, Xuan Wu Hospital Capital Medical University, Xicheng District, Beijing, 100053, People's Republic of China, Tel +86-1083198420, Email Background: Post-stroke depression (PSD) is one of the most common neuropsychiatric complications after stroke. However, the underlying mechanisms of PSD remain ambiguous, and no objective diagnosis tool is available to diagnose PSD. Previous metabolomic studies on PSD included patients with ischemic and hemorrhagic stroke indiscriminately, which is not conducive to elucidating and predicting the occurrence of PSD. The aim of this study is to elucidate the pathogenesis of PSD and provide potential diagnostic markers for PSD in ischemic stroke patients. Methods: In total, 51 ischemic stroke patients at 2 weeks were included in this study. Those with depressive symptoms were assigned to the PSD group, while the others were assigned to the non-PSD group. Plasma metabolomics based on liquid chromatography–mass spectrometry (LC-MS) was performed to explore the differential plasma metabolites between the PSD and non-PSD groups. Results: Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and orthogonal partial least-squares discriminant analysis (OPLS-DA) showed significant metabolic alterations between PSD patients and non-PSD patients. In total, 41 differential metabolites were screened out, mainly including phosphatidylcholines (PCs), L-carnitine and acyl carnitines, succinic acid, pyruvic acid and L-lactic acid. Metabolite-related pathway analysis revealed that alanine, aspartate and glutamate metabolism, glycerophospholipid metabolism and the citrate cycle (TCA cycle) may contribute to the pathogenesis of PSD. A panel of three signature metabolites [PC(22:5(7Z,10Z,13Z,16Z,19Z)/15:0), LysoPA(18:1(9Z)/0:0) and 1,5-anhydrosorbitol] was determined as potential biomarkers for PSD in ischemic stroke patients. Conclusion: These findings are conducive to providing new insights into the pathogenesis of PSD and developing objective diagnostic tools for PSD in ischemic stroke patients. Keywords: post-stroke depression, ischemic stroke, metabolomics, mechanisms, biomarker At present, stroke is one of the leading causes of serious long-term disability and mortality in China. One large nationally representative study showed that the incidence and mortality rates of stroke in China in 2020 were 505.2 per 100,000 person-years and 343.4 per 100,000 person-years, respectively. 1 Post-stroke depression (PSD) is one of the most common neuropsychiatric complications after stroke, affecting approximately 33% of stroke patients. 2,3 Specifically, one large cohort study with 157,243 stroke patients suggested that the incidence of depression in ischemic stroke patients was higher than that in hemorrhagic stroke patients within 2 years, at 28.0% and 23.3%, respectively. 4 Moreover, PSD is associated with a range of poor outcomes, including cognitive impairment, 5 low quality of life, 6 and enhanced all-cause mortality. 7 In clinical practice, PSD is always screened by subjective tools, such as the Hamilton Depression Rating Scale (HDRS) and nine-item Patient Health Questionnaire (PHQ-9), lacking objective diagnostic markers. 8 Indeed, PSD is often underdiagnosed and undertreated owing to the use of subjective tools and overlaps with other complex symptoms caused by stroke. 9 Therefore, it is necessary to find objective tools for the early diagnosis of PSD and thereby improve the prognosis of PSD patients. Many studies have found that PSD is a multifactorial disease, associated with gene polymorphism, 10 pre-stroke depression, 11 stroke severity, 12 lesion location, 13 social support 14 and years of education. 15 Numerous studies have aimed to propose theoretical hypotheses to explain the mechanism of PSD. For instance, overactivation of the hypothalamic–pituitary–adrenal (HPA) axis induced excessive release of cortisol and regulated neuron survival and neurogenesis, which is related to late-onset PSD (3 years). 16,17 Then, elevated neuroinflammation could influence every pathological domain of PSD, such as the HPA axis 18 and neurotransmitter metabolism. 19 Glutamate-mediated excitot -Abstract Truncated-
psychiatry,clinical neurology